title: Rapid kidney changes resulting from glycosphingolipid depletion by treatment with a glucosyltransferase inhibitor.
abstract: The ceramide analog, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol, inhibits the glucosylation of ceramide and thus, by virtue of the normal catabolism of the higher glucosphingolipids, leads to a general depletion of cellular glucolipids. In a previous study with chronic administration of this inhibitor in mice, it was found that the kidneys and liver, particularly the former, grew more poorly than the organs of control mice. This study shows that the inhibitor produces rapid decreases in glucolipid concentration in kidney which are maintained for at least 5 days without noticeable harm. The changes were enhanced by inclusion of L-cycloserine in the injection scheme. Cycloserine blocks ketosphinganine synthase and thus slows the synthesis of all sphingolipids. However, sphingomyelin levels did not drop significantly in this study. The glucosyltransferase inhibitor also produced a small decrease in kidney beta-D-glucuronidase and distinct increases in the levels of glucocerebrosidase, galactocerebrosidase and sphingomyelinase. It also produced a small but distinct decrease in the level of glucosyltransferase, after a delay of a few hours, possibly because the inhibitor was metabolized to a covalently inactivating product. Comparison with kidney, liver and brain showed that the kidney was more sensitive to the action of the morpholino inhibitor.
authors.affiliation: Mental Health Research Institute, University of Michigan, Ann Arbor.
authors.forename: G S
authors.initials: GS
authors.lastname: Shukla
authors.forename: A
authors.initials: A
authors.lastname: Shukla
authors.forename: J
authors.initials: J
authors.lastname: Inokuchi
authors.forename: N S
authors.initials: NS
authors.lastname: Radin
mesh_terms: D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D002518:Ceramides / Q000302:isolation & purification / Q000378:metabolism; D003523:Cycloserine / Q000494:pharmacology; D005696:Galactosidases / Q000378:metabolism; D005959:Glucosidases / Q000378:metabolism; D005963:Glucosylceramides / Q000302:isolation & purification / Q000378:metabolism; D005964:Glucosyltransferases / Q000037:antagonists & inhibitors*; D005966:Glucuronidase / Q000378:metabolism; D006028:Glycosphingolipids / Q000302:isolation & purification / Q000378:metabolism*; D007668:Kidney / Q000187:drug effects / Q000378:metabolism*; D007700:Kinetics; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D051379:Mice; D008813:Mice, Inbred ICR; D009025:Morpholines / Q000494:pharmacology*; D009928:Organ Specificity; D012016:Reference Values; D013108:Sphingomyelin Phosphodiesterase / Q000378:metabolism
chemical_list: D002518:Ceramides; D005963:Glucosylceramides; D006028:Glycosphingolipids; D009025:Morpholines; C033110:RV 538; D003523:Cycloserine; D005964:Glucosyltransferases; D013108:Sphingomyelin Phosphodiesterase; D005696:Galactosidases; D005959:Glucosidases; D005966:Glucuronidase